First Biotech to complete a Phase III for Long Hauler COVID-19 symptoms
First Biotech to complete a Phase III for Long Hauler COVID-19 symptoms
By Robert Millar | February 9, 2022 | Blog
EmphyCorp www.EmphyCorp.com is the first Biotech to complete a Phase III for COVID Long Hauler symptoms.
Our Patented Rx N115 Nasal Spray technology immediately clears the nose of congestion and increases Nasal Nitric Oxide to kill all viruses, bacteria, and fungi. It also improves breathing, increases Sa02 and lung functions. N115 reduces hypoxemia (low SaO2), fatigue, coughing/sneezing, trouble breathing, body aches, headaches in patients with Long Hauler COVID symptoms and improved all lung functions in patients with Pulmonary Fibrosis.
Dr. Martin, "Being a Non-Steroidal spray that increases nasal nitric oxide is key, because nasal steroids and other OTC nasal treatments shut down the synthesis of nasal nitric oxide, which then leads to decreased lung function and a 12%-34% increase in infections, depending upon age or underlying disease."
“Given our success in treating Pulmonary Fibrosis patients and the other respiratory diseases, our research focused on treating the symptoms in COVID-19 infected patients and in long hauler COVID patients, including hypoxemia (low SaO2), fatigue, coughing/sneezing, trouble breathing, body aches, headaches, and preventing lung fibrosis”.
There are approximately twelve million Americans with COVID-19 Long Hauler Symptoms, including athletes, which are at serious risk of developing Pulmonary Fibrosis (7-10% JAMA). Conversely, patients with Pulmonary Fibrosis have an increased risk and susceptibility to COVID-19 infection, which can reach a mortality rate of 50%. N115 is poised to help COVID-19 Long Haulers recover from this disease by reducing their symptoms including hypoxemia low (SaO2), fatigue, coughing/sneezing, trouble breathing, body aches, headaches, and lung damage.
EmphyCorp Patented Rx N115 Nasal Spray with no know side effects has successfully completed Phase III Clinical Trials for Pulmonary Fibrosis, COVID-19, and COVID Long Haulers.
To download the Press Release with Phase III Results, please go to the EmphyCorp Website PR-Newswire-EmphyCorp-Inc.-N115-Nasal-Spray-Completed-Phase-III-Clinical-Trial-for-COVID-19-Long-Haulers-and-Pulmonary-Fibrosis-100521.pdf (netdna-ssl.com)
Study evaluates treatment of ‘long COVID’ patients
Your source for what's happening at Missouri State University
Study evaluates treatment of ‘long COVID’ patients
N115 shows promise on debilitating symptoms.
November 2, 2021 by Strategic Communication
Fatigue, headaches, coughing and difficulty breathing: These symptoms affect daily life for people living with long COVID.
This is a condition marked by persistent symptoms long after a person initially recovered from COVID-19.
While so much is still unknown about how COVID-19 will continue to affect the health of those who survived, Dr. Christopher Lupfer, assistant professor of biology at Missouri State University, participated in a promising collaborative clinical trial.
He and the other researchers studied how N115, a natural product that consists of sodium pyruvate, reduces the symptoms of long COVID.
“Pyruvate is present in every cell of the body and is important for energy,” Lupfer said.
He also lists its antioxidant qualities, as well as its ability to increase nitric oxide, which improves lung function and fights infection.
The U.S. Food and Drug Administration is currently evaluating N115.
After participating in this study, Lupfer said, “N115 will hopefully be approved and marketed soon.”
Improved breathing, fewer headaches
The study included 22 patients with long COVID.
The research team monitored each patient for one week to establish a baseline of symptoms for each individual.
Then, they gave the patients N115 for one week. Their vital signs and symptoms were recorded and compared to the baselines.
“All 22 patients saw improvement in vital signs or disease symptoms compared to the week with no treatment,” Lupfer said.
This included improved breathing, less coughing and fewer headaches.
“Their blood oxygen levels also improved, demonstrating that patients were breathing better,” he added.
Coming together for greater results
The study was done in collaboration with:
- Emphycorp Inc.
- Dynamic DNA Labs.
- Trinity Healthcare.
- Family First Medical Research Clinic.
“We would like to thank Emphycorp for working with us to test this promising treatment, and our collaborators Dynamic DNA Labs, Trinity Healthcare and Family First Medical Research Clinic for their valuable support,” Lupfer said. “We especially thank the long COVID patients who participated in the clinical trial.”
The study is now published on ClinicalTrials.gov and the European Journal of Respiratory Medicine.
EmphyCorp Inc. Non-Steroidal N115 Nasal Spray Completed Phase III Clinical Trial for COVID-19, Long COVID-19 (Long Haulers), and Pulmonary Fibrosis
EmphyCorp Inc. Non-Steroidal N115 Nasal Spray Completed Phase III Clinical Trial for COVID-19, Long COVID-19 (Long Haulers), and Pulmonary Fibrosis
NEWS PROVIDED BY
Oct 05, 2021, 08:43 ET
FLEMINGTON, N.J., Oct. 5, 2021 /PRNewswire/ -- EmphyCorp Inc. www.EmphyCorp.com, a private corporation, specializes in Rx Non-Steroidal Nasal Spray Technology. Their flagship product, N115, has demonstrated efficacy, with no known side effects, for all lung and sinus diseases tested including COPD, Pulmonary Fibrosis, CF, Allergic Rhinitis, Chronic Rhinitis, Sinusitis, and Flu.
In 17 human clinicals (Phase I, II, III including animal safety data) submitted to the FDA, N115 produced statistically significant increases in all lung functions with the reduction in nasal and respiratory inflammation, a reduction in oxygen radicals, congestion, coughing, fatigue, and a reduction of inflammatory cytokines including IL-6, a cause of the cytokine storm in COVID-19 patients. N115 also increases the synthesis of nasal nitric oxide, a natural defence molecule that kills invading bacteria, fungi, and viruses to prevent and reduce the severity of infections.
Given our success in treating Pulmonary Fibrosis patients and the other respiratory diseases, our research focused on treating the symptoms in COVID-19 infected patients and in long hauler patients including: hypoxemia (low SaO2), fatigue, coughing/sneezing, trouble breathing, body aches, headaches, and Pulmonary Fibrosis.
These EmphyCorp (Cellular Sciences, the research arm of EmphyCorp) Clinical Trials included:
- Phase III in COVID-19 infected patients
- Phase III in COVID-19 Long Haulers (patients that had a COVID-19 infection and have persistent symptoms)
- Phase III in patients with Pulmonary Fibrosis
There are approximately 12 million Americans with COVID-19 Long Hauler Symptoms, including athletes, which are at serious risk of developing Pulmonary Fibrosis (7-10% JAMA). Conversely, patients with Pulmonary Fibrosis have an increased risk and susceptibility to COVID-19 infection, which can reach a mortality rate of 50%. Thus, N115 is poised to help protect patients from severe COVID-19 infections by improving Pulmonary Fibrosis lung function and for helping COVID-19 Long Haulers recover from this disease.
- In a Phase III Clinical Trial in Miami, FL with active COVID-19 infected patients, N115 lowered viral numbers below 10,000 viral genome copies by day 6.4, vs 10.3 days as reported for untreated patients. As reported in the literature, a reduction of viral numbers from over 100,000 to below 10,000 significantly decreases transmission of the virus. N115 clinically and significantly reduced coughing/sneezing, fatigue, and increased SaO2 levels.
- In a Phase III Clinical Trial in Springfield, MO and Miami, FL with COVID-19 Long Haulers, N115 clinically and significantly reduced coughing/sneezing, reduced headaches and body aches, increased SaO2 levels, and improved breathing.
- In a Phase III Clinical Trial with patients with Pulmonary Fibrosis, there was a statistically and clinically significant improvement in all lung functions, compared to baseline, including an increase in FEV-1, SaO2, FVC, FEV-1/FVC ratios (from 52% to 86%) and a reduction in coughing and fatigue.
EmphyCorp N115 Nasal Sprays have been used to treat over 3.5 million patients globally in 200 hospitals, with no adverse events. The clinical trials and summary results have been submitted to the FDA www.Clinicaltrials.gov (# NCT04824365 and # NCT04824365) website and will be available for public viewing soon. We were also invited to submit our results in the peer reviewed prestigious European Journal of Respiratory Medicine.
Dr. Alain Martin (CEO) believes:
"Based upon the results of our three Phase III Clinical Trials, EmphyCorp Rx N115 Non-Steroidal Nasal Spray could be used as a safe, effective treatment to help alleviate the symptoms associated with COVID-19 infections, Pulmonary Fibrosis, and Long COVID-19 (Long Hauler) symptoms."
"Being a Non-Steroidal spray that increases nasal nitric oxide is key, because nasal steroids and other OTC nasal treatments shut down the synthesis of nasal nitric oxide, which then leads to decreased lung function and a 12%-34% increase in infections, depending upon age or underlying disease."
EmphyCorp would like to enter into a Licensing Agreement and/or Joint Venture with a pharmaceutical company or company seeking to enter the respiratory drug market, both in the U.S. and foreign countries.
Please contact Robert Millar for more information at 973-586-4421 or EmphyCorp@optonline.net.
Dr. Alain Martin (7 US Drug Patents including Hypoxemia; 70+ Global Drug Patents) is the creator of our Worldwide Patented N115 Rx Non-Steroidal Nasal Spray Technology for COVID-19, COVID-19 Long Haulers, Pulmonary Fibrosis, Flu, and other OTC/Rx Respiratory Drugs. He also invented Advanced Neosporin, Neosporin Cold Sore Treatment, Advanced Therapy Lubriderm, Rx Rezulin (Rx Drug for Type II Diabetes), an FDA approved medium for lung and heart transplantation and Cool Mint Listerine.
SOURCE EmphyCorp Inc.
Related Links